Treatment of Thrombotic Thrombocytopenic Purpura in Pregnancy
A pair of researchers discuss the treatment and specific clinical challenges associated with thrombotic thrombocytopenic purpura in women who are pregnant.
A pair of researchers discuss the treatment and specific clinical challenges associated with thrombotic thrombocytopenic purpura in women who are pregnant.
Hospitalized patients with elevated Sdc-1 levels have a higher risk for death in patients with iTTP. Levels may be used for risk stratification.
A single-center study in Canada found a point prevalence of Gaucher disease of 0.5% among Canadian patients referred to a hematologist for thrombocytopenia.
Cerebral MRI data suggest that neurological symptoms and cognitive impairment may be common among patients with an acute TTP event.
Thrombotic thrombocytopenic purpura (TTP) related to systemic lupus erythematosus may not cause worse outcomes compared with primary immune-mediated TTP.
A team of investigators evaluated knowledge gaps among patients with TTP in remission and found a range of levels of understanding of the condition.
TTP is a rare disease that clinicians may not often treat; however, it is important to be aware of new developments for the treatment of this patient population.
Investigators conducted a large case series of CMV-linked thrombocytopenia to highlight treatment and response in immunocompetent adults.
Caplacizumab appears to be safe and effective among patients with acquired thrombotic thrombocytopenic purpura treated in the real-world setting.
Investigators developed an accurate prediction model for the early identification of refractory immune-mediated TTP.